

## Visudyne

## **CareFirst Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do\_not\_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	
Physician's Name:	
Specialty:	
Physician Office Telephone:	
<b>Referring</b> Provider Info: □ Same as Requesting	ng Provider
Name:	•
Fax:	Phone:
	g Provider 🗆 Same as Requesting Provider
Rendering Provider Info:   Same as Referring	
Name:	NPI#:
Name:  Fax:  Approvals may be subject to doss	NPI#: Phone: ing limits in accordance with FDA-approved labeling,
Name: Fax:  Approvals may be subject to dost accepted compendia,	NPI#:
Name:  Fax:  Approvals may be subject to doss	NPI#: Phone: ing limits in accordance with FDA-approved labeling, and/or evidence-based practice guidelines.
Name:  Fax:  Approvals may be subject to dost accepted compendia,  Required Demographic Information:	NPI#:
Name:  Fax:  Approvals may be subject to dost accepted compendia,  Required Demographic Information:  Patient Weight:  Patient Height:	NPI#: Phone: ing limits in accordance with FDA-approved labeling, and/or evidence-based practice guidelines. kgcm
Name: Fax:  Approvals may be subject to dost accepted compendia,  Required Demographic Information:  Patient Weight:	NPI#: Phone: ing limits in accordance with FDA-approved labeling, and/or evidence-based practice guidelines. kgcm sted drug:

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Visudyne SGM 3011-A – 6/2025

Criteria Questions:	
1. What is the diagnosis?	
☐ Predominantly classic subfoveal choroidal neovascularization (CNV), Continu	ue to 2
☐ Choroidal Hemangioma, <i>Continue to 3</i>	
☐ Other, please specify, No further questions	
<ul> <li>2. Is the patient currently receiving treatment with the requested medication?</li> <li>☐ Yes, Continue to 6</li> <li>☐ No, Continue to 4</li> </ul>	
3. Is the patient currently receiving treatment with the requested medication? ☐ Yes, <i>Continue to 6</i> ☐ No, <i>No further questions</i>	
4. Does the patient have predominantly classic subfoveal choroidal neovascularization following?	ation (CNV) due to one of the
☐ Yes, age-related macular degeneration, <i>Continue to 5</i>	
☐ Yes, pathologic myopia, <i>Continue to 5</i>	
☐ Yes, presumed ocular histoplasmosis, <i>Continue to 5</i> ☐ Yes, chronic central serous chorioretinopathy (also includes retinal pigment ep CNV), <i>Continue to 5</i>	oithelial leakage without evident
□ No, Continue to 5	
5. Is the treatment spot size less than or equal to 6.4 mm in diameter?  ☐ Yes, <i>No further questions</i> ☐ No, <i>No further questions</i>	
6. Has the patient demonstrated a positive clinical response to the requested medic ☐ Yes, <i>No further questions</i> ☐ No, <i>No further questions</i>	cation therapy?
I attest that this information is accurate and true, and that documentation information is available for review if requested by CVS Caremark or the l	
APrescriber or Authorized Signature D	ate (mm/dd/vv)
information is available for review if requested by CVS Caremark or the l	